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The neurobiological functions of a number of kinases expressed in the brain are unknown. Here, we report new ﬁndings on
DCLK3 (doublecortin like kinase 3), which is preferentially expressed in neurons in the striatum and dentate gyrus. Its function has
never been investigated. DCLK3 expression is markedly reduced in Huntington’s disease. Recent data obtained in studies related to
cancer suggest DCLK3 could have an anti-apoptotic effect. Thus, we hypothesized that early loss of DCLK3 in Huntington’s
disease may render striatal neurons more susceptible to mutant huntingtin (mHtt). We discovered that DCLK3 silencing in the
striatum of mice exacerbated the toxicity of an N-terminal fragment of mHtt. Conversely, overexpression of DCLK3 reduced
neurodegeneration produced by mHtt. DCLK3 also produced beneﬁcial effects on motor symptoms in a knock-in mouse model of
Huntington’s disease. Using different mutants of DCLK3, we found that the kinase activity of the protein plays a key role in
neuroprotection. To investigate the potential mechanisms underlying DCLK3 effects, we studied the transcriptional changes
produced by the kinase domain in human striatal neurons in culture. Results show that DCLK3 regulates in a kinase-dependent
manner the expression of many genes involved in transcription regulation and nucleosome/chromatin remodelling. Consistent with
this, histological evaluation showed DCLK3 is present in the nucleus of striatal neurons and, protein-protein interaction experi-
ments suggested that the kinase domain interacts with zinc ﬁnger proteins, including the transcriptional activator adaptor TADA3,
a core component of the Spt-ada-Gcn5 acetyltransferase (SAGA) complex which links histone acetylation to the transcription
machinery. Our novel ﬁndings suggest that the presence of DCLK3 in striatal neurons may play a key role in transcription
regulation and chromatin remodelling in these brain cells, and show that reduced expression of the kinase in Huntington’s disease
could render the striatum highly vulnerable to neurodegeneration.
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Introduction
Huntington’s disease is an inherited neurodegenerative dis-
order caused by a mutation of the huntingtin (HTT) gene.
The main hallmark of Huntington’s disease is the early loss
of medium-sized spiny neurons from the striatum. This
neuronal loss leads to striatal atrophy, followed by massive
progressive neurodegeneration throughout the brain.
Huntington’s disease is caused by an abnormal CAG
repeat expansion in the HTT gene (The Huntington’s
Disease Collaborative Research Group, 1993). Mutant
huntingtin (mHtt) is neurotoxic to neurons, particularly
medium-sized spiny neurons, through both gain- and loss-
of-function mechanisms (Zuccato and Cattaneo, 2014).
Mutant Htt causes transcriptional anomalies affecting the
expression of a large range of genes (Seredenina and Luthi-
Carter, 2012). It also causes changes in the cytoskeleton-
mediated transport machinery (Hinckelmann et al., 2013),
and defects in signalling pathways involved in cell survival
(Roze et al., 2008). However, none of these mechanisms
can account for the preferential damage to the striatum
observed early in the disease.
It has been suggested that factors selectively expressed in
the striatum may render GABAergic projection neurons
(medium-sized spiny neurons) particularly susceptible to
degeneration (Brouillet et al., 2005; Han et al., 2010;
Francelle et al., 2014). We previously performed a tran-
scriptome SAGE (serial analysis of gene expression)
analysis of different regions of the mouse brain, which
identiﬁed about 120 genes preferentially expressed in the
striatum (de Chaldee et al., 2003; Brochier et al., 2008).
Most of the products of these genes were conﬁrmed to be
‘striatal-enriched’ by checking against a freely available
transcriptomic database (e.g. Allen Brain Atlas). In our
initial screen, some of these newly identiﬁed striatal
gene products displayed signiﬁcantly lower than nor-
mal levels of expression in the brains of Huntington’s
disease mouse models (Brochier et al., 2008) and patients
(Kuhn et al., 2007). More recent studies conﬁrmed these
ﬁndings, showing that a subset of approximately 70 stri-
atal gene products (e.g. ADORA2A, DCLK3, GPR88,
RGS2, RGS9, SCN4B) are downregulated in knock-in
Huntington’s disease mice (Langfelder et al., 2016).
However, the functions of these striatal gene products are
frequently unknown, and their potential roles in the vulner-
ability of the striatum in Huntington’s disease remain a
matter of speculation.
For a few of these striatal genes, the effects of their
expression levels and/or inactivation have been assessed ex-
perimentally against the toxicity of mHtt in mice. Results
suggest that in some cases, the reduced expression of the
striatal marker found in the Huntington’s disease striatum
could lead to a loss of function rendering striatal cells more
vulnerable [e.g. the long non-coding RNA Abhd11os or
Crym (Francelle et al., 2015a, c)] while in others, it
might have no major impact on neurodegeneration
(e.g. capucin) (Galvan et al., 2012). In some instances, al-
though other striatal markers have reduced expression in
Huntington’s disease, they are considered as risk factors,
since the knock down of their genes or blockade of their
function produces neuroprotection against HTT toxicity.
For example, dopamine and its subtype 2 membrane recep-
tors (D2R), PDE10a, and the small GTPase Rhes have been
shown to be preferentially expressed in the striatum, have
early reduction of their expression in Huntington’s disease
patients and Huntington’s disease models and have been
shown to render striatal neurons highly vulnerable to
mHtt (Charvin et al., 2005, 2008; Benchoua et al., 2008;
Subramaniam et al., 2009; Giampa et al., 2010).
In the present study, we focused on a kinase of unknown
function, DCLK3. DCLK3 is the third member of the dou-
blecortin-like kinase (DCLK) family (Ohmae et al., 2006b).
The DCLK1/2 proteins have a conserved C-terminal ‘serine/
threonine kinase’ domain similar to that of Ca2+ /calmodu-
lin kinase IV (CaMKIV) and an N-terminal putative dou-
blecortin (DCX) domain mediating their anchorage to
microtubules. DCLK1 and DCLK2 are involved in neural
development and the maturation of neuronal architecture,
Neuroprotective properties of DCLK3 BRAIN 2018: 141; 1434–1454 | 1435
including the organization of dendritic spines in particular
(Kerjan et al., 2009; Shin et al., 2013) and play an import-
ant role in axonal regeneration mainly through their DCX
domain (Nawabi et al., 2015). DCLK3 functions are likely
not similar to those of DCLK1/2. The putative DCX
domain in the N-terminal part of DCLK1/2 is not present
in DCLK3. In addition, DCLK1 and DCLK2 have only
56–54% identities in the amino acid primary sequence of
DCLK3, with differences in and around the kinase domain
in the C-terminal part of the proteins. In line with this
hypothesis, DCLK3 displays a more neuron-speciﬁc pattern
of expression than DCLK1/2, which are also expressed in
astrocytes (http://web.stanford.edu/group/barres_lab/brain_
rnaseq.html) (Zhang et al., 2014). DCLK3 is mainly ex-
pressed in the adult and not in the developing forebrain.
Intriguingly, a recent study pointed to DCLK3 as an onco-
genic factor in colorectal cancer. High expression of
DCLK3 (resulting from at-distance effects of a single poly-
morphism in the promoter of the MLH1 gene) in cancer
cells was shown to be associated with increased malig-
nancy. This suggested that DCLK3 has biological functions
that may modulate cell survival (Liu et al., 2017).
We hypothesized that, if DCLK3 displays biological ac-
tivity favouring survival in neurons, then the loss of this
protein from neurons may contribute to striatal degener-
ation in Huntington’s disease. We investigated whether
the modulation of DCLK3 levels in mouse models of
Huntington’s disease affected mHtt toxicity in vivo. The
function of DCLK3 is unknown. Thus we performed dif-
ferent types of experiments to identify the signalling path-
ways or mechanisms through which the kinase activity of




Mice were housed (ﬁve/cage in enriched environment) in a
controlled-temperature room maintained on a 12-h light/dark
cycle. Food and water were available ad libitum. All ani-
mal studies were conducted in accordance with French
regulations (EU Directive 86/609 – French Act Rural Code R
214-87 to 131). The animal facility was approved by
veterinary inspectors (authorization no. A 92-032-02) and
complies with the Standards for Humane Care and Use of
Laboratory Animals of the Ofﬁce of Laboratory Animal
Welfare (OLAW – no. #A5826-01). All procedures were
approved by the ethics committee and the Research Ministry
[no. 2015060417243726vl (APAFIS#770)]. Adult male
C57BL/6J mice (each weighing 25 g; Charles River) were
used for lentiviral infections.
We also studied knock-in mice expressing a chimeric mouse/
human exon 1 containing 140 CAG repeats inserted into the
murine Htt gene (KI140CAG) and their control littermates.
The KI140CAG mouse colony was maintained by crossing
heterozygous KI140CAG males and females (Menalled et al.,
2003). Mice were N3 (B6) on a 129 Sv  C57BL/6J back-
ground. The resulting homozygous mice were used for the
study. Genotyping was performed by PCR on tail DNA ob-
tained from 10–15-day-old KI140CAG mice.
Lentiviral and AAV vector construction, production
and administration
DNA sequences encoding green ﬂuorescent protein (GFP) and
C-terminally haemagglutinin (HA)-tagged mouse short and
long forms of DCLK3 were inserted into the SIN-W-PGK len-
tiviral vector (de Almeida et al., 2002) to generate LV-GFP,
LV-S-rDCLK3-HA and LV-L-rDCLK3-HA, respectively. The
following PCR primers were used to generate S-rDCLK3-
HA: 50 CACCATGGGCAAAGAGCCGCTGAC 30 and 50
CTAGGAGGCGTAGTCAGGCACGTCGTATGGGTAGGC-
ACTGTTGGGGGACTCCTC 30.
We also cloned the C-terminal domain of DCLK3 (from
amino acid 330 to the C-terminal end) for expression of the
kinase domain alone, in the vector LV-Kin-rDCLK3-HA. The
LV-L-rDCLK3-HA and LV-Kin-rDCLK3 vectors were cloned
and produced by GeneArt based on the RNA sequence in the
GENE database. The HA-tag sequence was inserted just before
the stop codon.
We inserted short hairpin RNAs (shRNAs) targeting mouse
DCLK3 (target sequence: 50 GAGAAGTGTAAGAGAGAAA
3’) and luciferase (target sequence: 50 CGTACGCGGAA
TACTTCGA 30) into a bicistronic lentiviral vector (Drouet
et al., 2009), such that the infected cells expressed the reporter
protein GFP. The resulting constructs were designated
LV-DCLK3-shRNA and LV-Luc-shRNA, respectively. The len-
tiviral vectors expressing a wild-type Htt fragment
(LV-Htt171-18Q), a mutant Htt fragment (LV-Htt171-82Q)
or beta-galactosidase (LV-bgal) have been described elsewhere
(Diguet et al., 2009; Faideau et al., 2010). Lentiviral particles
were produced as previously described (Hottinger et al., 2000).
The particle content of the viral batches was determined by
ELISA for the p24 antigen (Gentaur).
For adeno-associated virus (AAV) production, the mouse L-
DCLK3 (rDCLK3) sequence was inserted into a single-stranded,
rAAV2-based shuttle vector under the control of the mouse
PGK promoter, by LR recombination, with Gateway technol-
ogy (Invitrogen, Life Technologies). All constructs were pack-
aged into AAVrh10 capsids by the MIRCen viral production
platform, as previously described (Berger et al., 2015). Viral
particles were produced by the transient co-transfection of
HEK-293 cells with an adenovirus helper plasmid (pXX6-80),
an AAV packaging plasmid carrying the rep2 and cap10 genes,
and the AAV2 transfer vector containing the expression cas-
settes described above. Virions were puriﬁed 72h after transfec-
tion and concentrated from the cell lysate and supernatant by
ultracentrifugation on an iodixaniol density gradient, followed
by dialysis against PBSMK [0.5mM MgCl2 and 1.25mM KCl
in phosphate-buffered saline (PBS)]. The concentration of the
vector stocks was estimated by quantitative PCR as described
by Aurnhammer et al. (2012) and expressed as the number of
viral genomes per ml of concentrated stocks (vg/ml).
LV-Htt171-82Q was used at a concentration of 150ng/ml of
p24; LV-S-rDCLK3-HA, LV-L-rDCLK3-HA, LV-Kin-rDCLK3-
HA, LV-DCLK3-shRNA, LV-Luc-shRNA and LV-bgal were
used at a concentration of 100ng/ml of p24, and LV-GFP at a
concentration of 50ng/ml of p24. AAV2/rh10-GFP and AAV2/
rh10-rDCLK3 were used at a dose of 2  109 vg per site.
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For intracerebral infections, animal were anaesthetized
(100mg/kg ketamine and 10mg/kg xylazine). Local analgesia
included subcutaneous lidocaine (5mg/kg). A volume of 2ml
of lentiviral or AAV suspension was injected into the mouse
striatum, as described (Faideau et al., 2010), at the following
stereotaxic coordinates: 1.0mm anterior and 2.0mm lateral to
bregma, at a depth of 2.7mm from the dura, with the tooth bar
set at 0.0mm. The mice were then left for 1–2h in a heated
(30C) ventilated box, until they had woken up and recovered
fully from anaesthesia. Post-surgery analgesia included acet-
aminophen (Doliprane) in drinking water for 48h (1.6mg/ml).
Behavioural tests on KI140CAG mice
KI140CAG mice receiving injections of AAV encoding GFP or
L-rDCLK3 at 6 months of age underwent behavioural tests at
12 months of age: the rotarod test, the CatWalk and grip
strength tests. We tested Huntington’s disease mice during
the light phase of the light/dark cycle. All the mice were
killed at the age of 13 months.
Rotarod
The rotarod test was used to evaluate the motor coordination
and strength of the mice. Eight-month-old mice were trained
on a rotarod (MED-Associates Rota-Rod) at 4 rpm for 2min.
They were then tested in three consecutive trials, each lasting
5min, in which the speed of the rod was increased from 4 to
40 rpm, with 45min between trials. This sequence was re-
peated on three consecutive days and values were averaged
across all trials.
Grip strength
A validated grip strength test meter (BIO-GS3 BIOSEB; EB
Instruments) was used to measure forelimb grip strength.
The mice were handled by their tails and placed over the
grid until they grasped the grid. The tail was then pulled
horizontally until the mouse released its grip fully. Three sep-
arate readings were recorded and the results, in grams, were
averaged for analysis.
CatWalk
The CatWalk XT gait analysis system (Noldus IT) used here
consisted of an enclosed walkway constructed from plate glass
and a camera for speed recording. Gait performance was as-
sessed with recording and analysis software. On the ﬁrst
2 days, the mice were allowed to get used to the apparatus
for 10min. This was considered to have been achieved if the
mouse crossed the walkway. The following day, free runs
across the walkway were recorded. A correct run was deﬁned
as one complete (60 cm) uninterrupted crossing of the walk-
way and a minimum of nine step sequences. We selected ﬁve
correct runs per animal for analysis. Body speed variation (%)
was calculated by dividing the absolute difference between
body speed and the mean speed of a run by the mean speed.
This parameter reﬂects the smoothness of mouse displacement
whilst crossing the walkway. The number of twitches captured
in the acquisition window during the run was determined.
These twitches corresponded to brief, sudden jerks of one of
the paws, resulting in a missing recording or a smaller paw
print, and an abnormal paw base.
Histological studies and image
analysis
Monkey tissue preparation
Serial coronal sections (40-mm thick) obtained from control
male adult Macaca fascicularis monkeys were ﬁxed in 4%
paraformaldehyde (PFA) and used for histological studies.
For DCLK3 immunohistochemistry, parafﬁn-embedded brain
sections were used.
Mouse tissue preparation
Mice were deeply anaesthetized by the intraperitoneal injection
of sodium pentobarbital solution (50 mg/g body weight). They
were then transcardially perfused with 100ml 4% PFA in
phosphate buffer at a ﬂow rate of 8ml/min. The brains of
the animals were removed, post-ﬁxed overnight in the same
solution, then cryoprotected by immersion in 30% sucrose
for 36 h. Free-ﬂoating 30-mm serial coronal sections from
throughout the striatum were collected with a freezing sliding
microtome (SM2400; Leica Microsystems). Brain slices were
placed in a storage solution (30% glycerol, 30% ethylene




Brain slices were subjected to pretreatment with 0.3% hydro-
gen peroxide for 1 h, washed three times in PBS, blocked in
PBS containing 4.5% normal goat serum (NGS) for 1 h, then
incubated overnight at 4C in PBS containing 3% NGS, 0.2%
TritonTM X-100 and anti-DCLK3 antibody (1:1000, rabbit,
21890002, Novus). The brain slices were then rinsed and incu-
bated with biotinylated secondary antibodies (Vector
Laboratories) for 1 h at room temperature. Finally, slices
were incubated with the Vectastain Elite ABC Kit (Vector
Laboratories) and antibody binding was detected with DAB
(Vector Laboratories).
Mice
Free-ﬂoating sections were subjected to pretreatment with
0.3% hydrogen peroxide for 1 h, washed three times in PBS,
blocked in PBS containing 4.5% NGS for 1 h, then incubated
overnight at 4C in PBS containing 3% NGS, 0.2% TritonTM
X-100 and one of the following antibodies: anti-DARPP32
(1:1000, rabbit, Santa Cruz Biotechnology), anti-NeuN
(1:2000, mouse, Millipore), anti-ubiquitin (1:1000, rabbit,
Wako Chemicals), or anti-HA (1:500, mouse, clone 11
Covance). Sections were rinsed three times in PBS and then
incubated with the appropriate anti-IgG biotinylated antibody
(Vector Laboratories) at a dilution of 1:5000, for 1 h. Staining
was visualized by adding avidin-biotinylated peroxidase and
incubating with DAB or VIP substrate (Vector Laboratories)
for 1min. For NeuN immunostaining, we used the MOM
immunodetection kit (Vector Laboratories). Stained sections
were mounted on microscopy slides.
Cytochrome c oxidase histochemistry
Brain slices were incubated in 0.1M phosphate buffer, 4%
sucrose, 0.05% DAB (Vector Laboratories), and 0.03% cyto-
chrome c (Sigma-Aldrich) for 6 h at room temperature. Slices
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PFA-ﬁxed coronal sections of the striatum were treated with
0.5% citrate buffer in a 75C water bath for 20min to maxi-
mize antibody penetration into the tissue. Non-speciﬁc Fc-
binding sites were blocked by incubation with 4.5% NGS
for 1 h and sections were then incubated overnight at 4C
with anti-NeuN antibody (1:1000, mouse, Millipore). The sec-
tions were rinsed three times in PBS and incubated with anti-
DCLK3 antibody (1:1000, rabbit, 21890002, Novus). Both
primary antibodies were diluted in PBS supplemented with
3% NGS and 0.2% TritonTM X-100. We used the Tyramide
Signal Ampliﬁcation Kit (Life Technologies), according to the
manufacturer’s protocol, for high-density DCLK3 labelling.
For NeuN labelling, sections were rinsed three times in PBS
and incubated for 1 h with Alexa Fluor 488-conjugated goat
anti-mouse secondary antibody (1:1000, Life Technologies).
They were then rinsed again and incubated in 40,6-diami-
dino-2-phenylindole (DAPI) diluted 1:2000 in PBS for 10
mins, before a ﬁnal rinse in PBS and mounting.
Mice
For the detection of DCLK3 by immunoﬂuorescence after in-
fection with LV-rDCLK3-HA in mouse striatum, free-ﬂoating
sections were prepared as described above. These sections were
blocked by incubation with 4.5% NGS in PBS for 1 h, then
incubated overnight at 4C in PBS supplemented with 3%
NGS, 0.2% TritonTM X-100 and one of the following anti-
bodies: anti-HA (1:500, mouse, clone 11, Covance) or anti-
DCLK3 (1:1000, rabbit, 21890002, Novus). Sections were
rinsed three times in PBS and incubated with Alexa Fluor
488-labelled anti-mouse IgG or Alexa Fluor 594-labelled
anti-rabbit IgG (Invitrogen) at room temperature for 1 h. The
sections were rinsed in PBS and the nuclei were counterstained
with DAPI (dilution 1:10 000, Wako) for 3 mins.
Confocal microscopy
Immunoﬂuorescent labelling was analysed with a confocal
laser-scanning microscope (SP8 Leica).
Image analysis of lesion area
The area covered by striatal lesions resulting from LV-Htt171-
82Q infection was delineated manually by identifying the
border of the lesion on each coronal brain section. The corres-
ponding area was calculated with MCID image analysis soft-
ware (InterFocus Imaging). The volume of the striatal lesion
was determined by the Cavalieri method and the number of
ubiquitin-positive inclusions was determined as previously
described (Diguet et al., 2009; Francelle et al., 2015b, d) with
an intersection distance of 210mm (i.e. we used one in every
seven sections). A 10 objective was used on an Axioplan 2
imaging microscope (Carl Zeiss). Objects with an apparent
cross-sectional area exceeding 5mm2 were reliably detected
with this method.
Real-time quantitative RT-PCR and northern blot
analysis
Adult mice were deeply anaesthetized by the intraperitoneal in-
jection of sodium pentobarbital solution (50mg/g of body weight)
and decapitated. The brains were immediately removed and pos-
itioned in a coronal brain matrix (Ted Pella). For DCLK3
mRNA determinations in knockdown experiments, we examined
1-mm brain sections under a ﬂuorescence microscope (DM6000
M; Leica Microsystems) and sampled the striatal area expressing
the GFP reporter protein with a 1.5-mm diameter hole-punch
(Ted Pella). We quantiﬁed DCLK3 levels by dissecting out the
striatum of the mice on 1-mm thick sections, with a scalpel. Total
RNA was extracted with TRIzol (Invitrogen) and treated with
RQ1 DNase (Promega). cDNA was synthesized with the
SuperScriptTMViloTM cDNA synthesis kit (Invitrogen), and
qPCR was performed with the Platinum Taq enzyme (SYBR
Green PCR kit, Invitrogen) on a Master cycle Realplex system
(Eppendorf) using the primers 50 TGGGCGGCAGGTGTGAT 30
and 50 GCTCGTCTTGGTCCCTCTCAG 30 for DCLK3.
For northern blot analysis, a 5-mm thick block containing
the entire striatum (between grooves 3 and 8 of the matrix,
groove 1 being the most anterior) was removed from each
brain and processed for mRNA extraction (Brochier et al.,
2008). We denatured 3 mg of poly(A) + RNA in glyoxal-
dimethylsulfoxide solution and subjected it to electrophoresis
in a 1% agarose gel. The bands were then transferred to a
HybondTM -XL nylon membrane (GE Healthcare) and hybrid-
ization was carried out at 65C in Rapid-Hyb buffer (GE
Healthcare) with an [-32P]dCTP random primed (Prime-It
II; Agilent Technologies) 788-bp PstI fragment of the
DCLK3 cDNA sequence as a probe (Fig. 1A).
Tissue processing and western blotting
Primate tissue and fractionation experiments
For biochemical studies, we used control frozen macaque
(M. fascicularis) brain samples, as previously described
(Francelle et al., 2015a). All procedures conformed to
European (European Union Directive 86/609/EEC) and
French (French Act Rural Code R 214-87-131) regulations.
The animal facility was approved by veterinary inspectors
(Authorization 92-032-02) and complied with the Standards
for Humane Care and Use of Laboratory Animals of the
Ofﬁce of Laboratory Animal Welfare (A5826-01). For frac-
tionation experiments, a frozen piece of tissue (100mg)
was placed in a loose-ﬁtting Dounce homogenizer with
2.0ml of buffer A [10 mM HEPES pH 7.9, 150mM NaCl,
1mM EDTA, 10 ml/ml protease inhibitors (Roche), 10 ml/ml
phosphatase inhibitors (Sigma-Aldrich)] and homogenized
with 10 up-and-down passes. We added 100 ml of 10% NP-
40 (0.5% ﬁnal concentration) and the mixture was fully
homogenized by 15 up-and-down passes. All these steps
were performed on ice. The homogenate was transferred to
an Eppendorf tube and incubated on ice for 10min. We
used 1ml of homogenate as the total fraction. The rest was
centrifuged for 10min at 100g at 4C. The supernatant was
retained as the cytosolic fraction. The pellet was homoge-
neously suspended in 500ml buffer A and centrifuged at
100g for 10min at 4C. The supernatant was discarded. The
pellet was suspended in 250ml buffer B [20 mM HEPES pH
7.9, 420mM NaCl, 1.2mM MgCl2, 0.2mM EDTA, 25%
glycerol, 0.5mM dithiothreitol (DTT), 10 ml/ml protease
inhibitors, 10 ml/ml phosphatase inhibitors] and vortexed to
constitute the nuclear fraction. Each fraction was sonicated
for 20 s at 20% amplitude. The nuclear fraction was vortexed
at 5-min intervals over a 20-min period. Each fraction was
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then centrifuged at 16 000g for 40min at 4C. Protein concen-
tration was determined by the Bradford method (Thermo
Scientiﬁc).
Mouse tissue
Mice were killed with an overdose of sodium pentobarbital,
and their brains were rapidly collected and sliced into 1-mm
thick coronal sections with a brain matrix. The striatum was
dissected out and homogenized with a glass homogenizer in
50mM Tris-HCl, pH 7.4, 100mM NaCl, and 1% SDS, with
protease (Roche) and phosphatase inhibitor cocktails (Sigma-
Aldrich). Protein concentration was determined by the BCA
method (Thermo Scientiﬁc).
Western blot
Protein samples were diluted in NuPAGE LDS sample buffer
with NuPAGE Sample Reducing agent (Life Technologies),
boiled for 5min, loaded on a 4–12% Bis-Tris gel (Life
Technologies), and subjected to SDS-PAGE. The bands ob-
tained were then transferred to a nitrocellulose membrane
with an iBlot transfer device (Life Technologies).
Membranes were incubated overnight at 4C with antibodies
against HA (1:2000, mouse, Covance), DCLK3 (1:1000,
21890002, rabbit, Novus), or beta-tubulin (1:2000, mouse,
Sigma-Aldrich) diluted in Tris-buffered saline supplemented
with 0.1% Tween 20 and 5% bovine serum albumin (BSA).
The membranes were rinsed and incubated with horseradish
peroxidase-conjugated secondary antibodies for 1 h (1:4000,
GE HealthCare). Antibody binding was detected with a
Fusion FX7 camera system (Thermo Fisher Scientiﬁc) after
incubation with the Clarity enhanced chemiluminescence sub-
strate (Bio-Rad).
In vitro experiments
Directed mutagenesis of DCLK3
S-DCLK3-HA was subjected to in vitro mutagenesis with the
QuikChange Site-Directed Mutagenesis Kit (Stratagene), to
replace the threonine 286 residue (i.e. threonine 457 in L-
DCLK3) with an alanine residue (T286A), with the following
primers: T286A-F: 50 CCACAGCTACCTAGAGCCCGAGGG
GAGGAG 30 and T286-R: 50 CTCCTCCCCTCGGGCTCT
AGGTAGCTGTGG 30. The lysine 543 residue of L-DCLK3-
HA and Kin-DCLK3 was mutated to a methionine (K543M)
with the following primers: K543M-F: 50 GACAAAGCA
GGCATATGCCATGATGATGATTGACAAGAGC 30 and
K543M-R: 50 GCTCTTGTCAATCATCATCATGGCATATG
CCTGCTTTGTC 30. A silent mutation was also added to
introduce an NdeI site, to facilitate sequence veriﬁcation.
Primary culture of neurons and transfection/
infection
Primary cultures of striatal neurons were set up and main-
tained as previously described (Benchoua et al., 2008). These
neurons were electroporated with the mouse striatal neuron
Nucleofector kit according to the instructions supplied
(Amaxa, Biosystem).
Primary cortical neurons were prepared from embryonic Day
17 rat embryos. Brieﬂy, cortices were dissected in cold Hank’s
Balanced Salt Solution (HBSS) supplemented with 10mM
HEPES. Tissue digestion was performed with a 10-min incu-
bation in a 0.025% trypsin solution. Enzymatic action of the
Figure 1 DCLK3 knockdown increases the toxicity of mHtt
in vivo. Mice received lentiviral vectors encoding a shRNA targeting
either DCLK3 (shDCLK3) or luciferase (shCTRL, the control). The
shRNA-encoding constructs also contained the coding sequence for
GFP. (A) Representative images of GFP expression in striatal sections
from mice infected with LV-Htt171-82Q or LV-Htt171-18Q with
LV-shDCLK3 or its control (LV-shCTRL) (3 weeks post-infection).
(B) Quantification of fluorescence as an index of neuronal integrity
in mice infected with LV-Htt171-18Q mixed with LV-shCTRL
(control levels of GFP) or LV-Htt171-82Q mixed with LV-shDCLK3
or LV-shCTRL. Quantification was performed 3 and 6 weeks
after infection. The Htt171-82Q-induced loss of GFP was
exacerbated by LV-shDCLK3. (C) Brains were processed for
histological evaluation 6 weeks after infection, with DARPP32
histochemistry used to detect Htt171-82Q toxicity. Left: Typical
coronal sections of mouse brain, with areas of staining depletion
observed in the presence of Htt171-82Q. Right: Quantitative
determination of the size of the striatal lesions in the two groups.
Infection with shDCLK3 significantly leads to increased lesion
volume, as shown with DARPP32. Results are expressed as
means (n = 7–10/group)  SEM. Mann-Whitney and Kruskall-Wallis
tests in B and paired Student’s t-test in C. Scale bars in A = 0.25 mm;
B = 0.5 mm.
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trypsin was inactivated by addition of 1ml of foetal calf
serum. After 3 washes in 5ml HBSS supplemented with
10mM HEPES, cortices were mechanically dissociated by 10
up-and-down movements. Neurons were plated on glass cover-
slips coated with poly-L-lysine (1mg/ml) in Neurobasal + 2%
B27 + 1% penicillin/streptomycin. Cells were maintained in
5% CO2 and humidity atmosphere.
HEK 293T cells and transfection
HEK293T cells were cultured in Dulbecco’s modiﬁed Eagle
medium (DMEM, Wako) supplemented with 10% foetal
bovine serum and 1% phenylalanine-streptomycin (Sigma-
Aldrich). Cells were grown at 37C in a damp incubator,
under an atmosphere containing 5% CO2/95% air.
HEK293T cells were plated at a density of 7.5  105 cells
per well in six-well plates or 10  104 cells per well in
24-well plates. After 24 h of culture, cells were transfected by
the calcium phosphate (CaPO4) transfection method, with a
maximum of 5mg of plasmid DNA. They were incubated for
4 to 6 h in DMEM supplemented with 10% foetal bovine
serum and 1% phenylalanine-streptomycin, and the medium
was then replaced. Cells were processed 48 h after transfection
to ensure optimal protein expression.
Immunofluorescence of DCLK3 and rDCLK3-HA in
HEK293T cells and neurons
HEK293T
Transfected cells were cultured on poly-L-lysine-coated 12mm-
diameter coverslips and treated with 100% ice-cold methanol
and 5mM EGTA for 3min to preserve the microtubular net-
work. The ﬁxed cells were rinsed with TBS (0.02M Tris-HCl
pH 7.4, 0.15M NaCl), and permeabilized by incubation with
0.1% Triton
TM
X-100 in blocking solution [TBS, 1% bovine
serum albumin (BSA)] for 30min. The cells were then incu-
bated with anti-HA antibody (1:1000, mouse clone11,
Covance) or anti--tubulin antibody (1:1000, rabbit,
Millipore) diluted in 1% BSA in TBS-0.1% Triton
TM
X-100,
at room temperature for 1 h. The cells were then incubated
with Alexa Fluor 594-labelled anti-mouse IgG or Alexa
Fluor 488-labelled anti-rabbit IgG (Invitrogen), respectively,
at room temperature for 30min. They were rinsed in TBS and
treated with DAPI (1:10 000, Wako) diluted in TBS, at room
temperature for 3min, and were then observed under a con-
focal laser-scanning microscope (SPE and SP8 Leica).
Neuronal cultures
Cortical rat primary neurons were ﬁxed with cold methanol
during 5min at 20C then washed twice with PBS. Similar
treatment was used for human neurons except that cells were
ﬁxed with PFA 4%. Blocking was performed with PBS + 3%
NGS + 0.1% TritonTM X-100. Primary antibodies (anti-Dclk3
1/500 and anti-HA 1/1000) were incubated overnight at 4C
in the blocking buffer followed by three washes in the same
buffer. Secondary antibodies conjugated with Alexa ﬂuoro-
chromes (anti-rabbit Alexa Fluor 488 and anti-mouse Alexa
Fluor 594, 1/500) prepared in the blocking buffer were incu-
bated during 1 h at room temperature. After two washes in the
blocking buffer, a staining with Hoechst 33258 (1mg/ml in
PBS) was performed during 5min at room temperature fol-
lowed by two washes in PBS. Coverslips were mounted in
Mowiol before confocal microscopy.
DCLK3 antibody pre-blocking experiment
For the DCLK3 blocking peptide experiment, the DCLK3 anti-
body (Ab2189, Novus) was incubated (ratio of 1:5 with either
H2O or the recombinant human DCLK3 protein) (ProteoGenix)
overnight at 4C under agitation. This step was performed
in tubes previously coated with BSA (5min incubation with
1mg/ml of BSA in Tris 50mM and NaCl 150mM followed
by three washes with H2O). Immunostaining was performed
as described above.
Immunoprecipitation for the autophosphorylation
assay
Cells were collected 48 h after transfection and lysed in mod-
iﬁed-RIPA buffer [10 mM Tris–HCl (pH 8.0), 1% NP-40,
150mM NaCl, 1mM EDTA, 10 mg/ml protease inhibitors
(Mini-Complete, Roche) and 1% phosphatase inhibitor cock-
tail 2 (Sigma-Aldrich)]. The homogenates were centrifuged at
16 000g for 20min, and the supernatants were collected.
Protein levels were determined by the BCA method.
We used the IP/co-IP kit, with magnetic beads coupled to
A/G protein (Thermo Fisher). We rinsed 50 ml of magnetic
beads and incubated them for 2 h with antibodies [0.5 mg of
anti-HA antibody or anti-TADA3 antibody (NBP1-90243,
rabbit, Novus)] at 4C. We mixed 500mg of total protein ex-
tract with the antibody-bead complex and incubated the mix-
ture at 4C for 3 h.
For immunoprecipitation for the autophosphorylation assay,
the beads were rinsed in kinase assay buffer (25mM HEPES
pH 7.4; 25mM, MgCl2) supplemented with inhibitors
(0.1mM orthovanadate, 25mM b-glycerophosphate) and
2mM DTT. For autophosphorylation assays, we added
20 mM unlabelled ATP. For protein kinase activity determin-
ation, we added 6000Ci/mmol [-32P]ATP to the beads and
incubated at 20C for 30min (or eluted with SDS-PAGE
sample buffer for SDS-PAGE analysis). The beads were
rinsed several times with the kinase assay buffer before incu-
bation in 20 ml NuPAGE LDS Sample Buffer (4 ) at 80C
for 5min. The supernatant was subjected to electrophoresis in
a precast gel (NuPAGE Novex 4–12% Bis-Tris Protein gel,
Invitrogen). The gel was dried at 60C for 3 h and then placed
against a MultiSensitive phosphor screen (Perkin Elmer) for 2 h
in the dark. This sensitive screen was used to measure radio-
activity levels, with the high-resolution ﬁlmless Cyclone Plus
Phosphor Imager autoradiography system (PerkinElmer).
For immunoprecipitation of kinase assays, the beads were
rinsed with kinase assay buffer supplemented with inhibitors.
For kinase assays with myelin basic protein (MBP) as a uni-
versal kinase substrate, we incubated beads in 200 mM
unlabelled ATP and 5mg/ml MBP at 30C for 60min. The
reaction was stopped by adding NuPAGE LDS Sample
Buffer (4 ) incubating at 80C for 5min. The supernatant
was run on a precast gel (NuPAGE Novex 4-12% Bis-Tris
Protein gel, Invitrogen).
For immunoprecipitation for the TADA3-rDCLK3 inter-
action study, we used a two-step immunoprecipitation proto-
col. The beads were incubated with antibodies and protein
extracts from cells transfected with plasmids coding mouse
Kin-rDCLK3 or human TADA3 and then rinsed several
times. We then incubated the beads for 2 h with protein ex-
tracts from cells transfected with TADA3 or rDCLK3, respect-
ively. The beads were rinsed and the proteins eluted by boiling
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the beads in NuPAGE LDS Sample Buffer (4 ) at 80C for
5min.
Western blotting
SDS–PAGE was performed on NuPAGE Novex 4-12% Bis-
Tris pre-cast polyacrylamide gels (Invitrogen). We used iBlot
Transfer Stacks and the iBlot Gel Transfer Device (Thermo
Fisher Scientiﬁc) for protein transfer. The 7-min transfer
programme efﬁciently transferred most of the proteins.
Yeast two-hybrid analysis
Yeast two-hybrid screening was performed by Hybrigenics
Services (http://www.hybrigenics-services.com). The coding se-
quence for human DCLK3 (GenBank accession number gi:
149589020) was ampliﬁed by PCR and inserted into pB29
as an N-terminal fusion to LexA (N-DCLK3-LexA-C). The
construct was checked by sequencing the entire insert and
used as bait for screening a random-primed human adult
brain cDNA library constructed in pP6. The pB29 and pP6
constructs were derived from the original pBTM116 (Vojtek
and Hollenberg, 1995; Beranger et al., 1997) and pGADGH
(Bartel et al., 1993) plasmids, respectively.
We screened 110 million clones (11-fold coverage) by a
mating approach, with YHGX13 (Y187 ade2-101::loxP-
kanMX-loxP, mat) and L40Gal4 (mata) yeast strains, as
previously described (Fromont-Racine et al., 1997). We se-
lected 36 His + colonies on a medium lacking tryptophan,
leucine and histidine. The prey fragments of the positive
clones were ampliﬁed by PCR and their 50 and 30 junctions
were sequenced. The resulting sequences were used to identify
the corresponding interacting proteins in the GenBank data-
base (NCBI) by a fully automated procedure. A conﬁdence
score (predicted biological score) was attributed to each inter-
action, as previously described (Formstecher et al., 2005).
The protein interactions from this publication have been
submitted to the IMEx (http://www.imexconsortium.org) con-
sortium through IntAct (Orchard et al., 2014) and assigned the
identiﬁer IM-26152.
Human embryonic stem cell-derived neuronal sam-
ples and transcriptomic analyses
RC9 human embryonic stem cells (XY, passage 20–40; Roslin
Cells) were maintained on CELLstartTM (Invitrogen) and cul-
tured in STEMPRO medium (Invitrogen; cultures were fed
daily and manually passaged every 4–5 days).
Striatal neuron progenitors were derived from human em-
bryonic stem cells as previously described (Nicoleau et al.,
2013; Arber et al., 2015). Brieﬂy, human embryonic stem
cell colonies were manually dissociated and suspended for
6 h in neural induction medium consisting of DMEM/F12,
Neurobasal, N2 and B27 supplement, b-mercaptoethanol
and penicillin/streptomycin (N2B27 medium) supplemented
with 0.1 mM LDN-193189 (Miltenyi Biotec), 20 mM SB-
431542 (Tocris), 1 mM XAV-939 (Cellagen Technology) and
10 mM ROCK inhibitor (Y27632, Calbiochem). On Day 1,
human pluripotent stem cell-aggregates were transferred to
polyornithine laminin-coated dishes without Y27632. On
Day 10, LDN-193189 and SB-431542 were removed and
cells were cultured for a further 10 days in N2B27 supple-
mented with 50 ng/ml activin A (R&D Systems). On Day 21,
striatal progenitors were passaged with Accutase for
10–20min at 37C and plated on polyornithine laminin-
coated dishes at 80–100 thousand cells per square centimetre
in terminal speciﬁcation medium consisting of N2B27 supple-
mented with 20 ng/ml BDNF (R&D Systems), 0.5mM
dbcAMP (Sigma–Aldrich), 0.5mM valpromide (Lancaster
Synthesis) and 50 ng/ml activin A (R&D Systems) for 24 add-
itional days of culture.
After 15 days of neuronal differentiation, post-mitotic neur-
onal cultures were transduced with 24 ng of lentiviral vectors
encoding GFP, wild-type Kin-rDCLK3 or rDCLK3-K543M.
These infected neuronal cultures were processed for total
RNA extraction 10 days after infection, with the RNeasy
Plus Micro Kit (Qiagen). For the large scale RNA study,
each of the 16 samples, were reverse-transcribed (50 ng of
total RNA) with the Ion AmpliSeq Transcriptome Human
Gene Expression kit (Revision A.0) according to the manufac-
turer’s protocol (Life Technologies). The cDNA libraries were
ampliﬁed and barcoded with the Ion AmpliSeq Transcriptome
Human Gene Expression core panel and the Ion Xpress
Barcode Adapter (Life Technologies). The amplicons were
quantiﬁed with the Agilent High Sensitivity DNA kit and the
samples were then pooled in sets of six. Emulsion PCR and
Enrichment and loading onto the Ion Chef Instrument were
performed with the Ion PI IC 200 Kit (Life Technologies).
Samples were loaded on an Ion PI v2 BC Chip and sequenced
on the Ion Proton System by Ion PI IC 200 Kit chemistry (200-
bp read length; Life Technologies). The Ion Proton reads
(FASTQ ﬁles) were imported into the RNA-seq pipeline of
Partek Flow software (v 4.0, Partek Inc), with hg19 as the
reference genome. We identiﬁed genes differentially expressed
between groups, by quantifying mapped reads with the Partek
E/M algorithm (the resulting counts represent the expression
levels of more than 20 800 different genes present in the
AmpliSeq Human Gene Expression panel) and applying the
Partek Gene Speciﬁc Analysis (GSA) algorithm. The data
of this experiment have been deposited on GEO under acces-
sion number GSE104091. For the RT-PCR study of human
striatal neurons infected with LV-Htt171-82Q, the protocol
for RNA extraction and analysis was similar to that described
above.
The ﬁrst analysis involved identifying the genes differentially
expressed between Kin-rDCLK3WT and GFP for ontology
analysis. Relatively stringent criteria were used [fold-change
41.20 and adjusted P5 0.0005, false discovery rate
(FDR)50.05].
The second analysis involved identifying the genes for which
expression was speciﬁcally regulated by the activity of the kinase
domain. We searched for genes displaying expression changes
triggered by kin-rDCLK3WT and not Kin-rDCLK3K543M. We
used a lower stringency to identify genes displaying differences
in expression between Kin-rDCLK3WT and GFP conditions [Fold
Change (FC)4 1.1, adjusted P50.0009, FDR50.05, 275
genes, Supplementary Table 3] and between Kin-rDCLK3K543M
and Kin-rDCLK3WT conditions (FC4 1.1, adjusted P50.002,
FDR5 0.05; 371 genes, Supplementary Table 4).
Biological interpretations of the list of differentially ex-
pressed genes were obtained with dedicated software [Partek
Genomics Suite (v6.6), Gene Set Enrichment Analysis (GSEA)
software from the Broad Institute (http://www.broadinstitute.
org/gsea) or online with DAVID (Huang da et al., 2009) and
GREAT (McLean et al., 2010)].
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Statistical analysis
All data are expressed as means  standard error of the mean
(SEM). Normality of data distribution was tested using the
Shapiro-Wilk test and homogeneity of variance was tested
with Levene’s test using the commercially available software
(Statistica, 13.0). When normality and homogeneity of vari-
ance were met (on raw or log transformed data), unpaired
Student’s t-tests were used for pairwise comparisons between
groups. For comparisons of more than two groups, one-way
ANOVA for multiple comparisons was carried out, with
Fisher’s post hoc partial least-squares difference (PLSD) test.
In the cases where assumption of normality and/or homogen-
eity of variance are not met, non-parametric tests were applied:
Mann-Whitney and Kruskall-Wallis for comparison of two
and more groups, respectively.
Results
DCLK3 downregulation exacerbates
mHtt toxicity whereas overexpres-
sion is neuroprotective in vivo
The mouse Dclk3 gene sequence has two open reading
frames corresponding to a large (L-DCLK3, 790 aa) and a
short (S-DCLK3, 619 aa) form of DCLK3 (Supplementary
Fig. 1). Both forms (L-DCLK3 and S-DCLK3) contain the
full conserved kinase sequence, but only L-DCLK3 has a
putative DCX domain (Supplementary Fig. 1A). Macaques
and humans have only one open reading frame, encoding a
648 aa protein displaying high levels of similarity to the
mouse S-DCLK3. Northern blot analysis with mRNA
from adult mouse brains showed that L-DCLK3 was more
strongly expressed than S-DCLK3 (Supplementary Fig. 1B).
Dclk3 mRNA levels were much higher in the striatum than
in other regions of the brain, consistent with previous ﬁnd-
ings (Brochier et al., 2008) and available transcriptomic
datasets (http://mouse.brain-map.org/experiment/show/
72079921). We also checked that DCLK3 is an active
kinase. Recombinant mouse long- and short-forms of
DCLK3 with a HA-tag (termed hereafter L- or S-rDCLK3-
HA) were produced in HEK293 cells, puriﬁed by immuno-
precipitation and tested in an autophosphorylation assay
with [-32P]ATP. The autophosphorylation of proteins
with apparent molecular weight corresponding to those of
full-length S-rDCLK3 and L-rDCLK3-HA, respectively, was
easily detected (Supplementary Fig. 1C).
First, we analysed the role of each mouse DCLK3 form, by
using lentiviral vectors. As DCLK3 levels are low in
Huntington’s disease patients and mouse models (Kuhn
et al., 2007; Brochier et al., 2008; Langfelder et al., 2016),
we investigated whether the silencing of the endogenous
mouse protein using a lentivirus coding a shRNA targeting
Dclk3 mRNA (LV-shDCLK3) aggravated mHtt toxicity
in vivo. As a control, we used a shRNA targeting luciferase
(shCTRL), a non-mammalian gene. Both vectors contained a
GFP reporter gene (Supplementary Fig. 2A) and no difference
in GFP ﬂuorescence was observed in the striatum at 4 weeks
post-infection when the two lentiviral shRNAs were com-
pared (Fig. 1A and B). Thus, transduction and expression
levels may therefore be considered to have been similar for
both lentiviruses (Fig. 1B). RT-qPCR showed that shDCLK3
decreased endogenous Dclk3 mRNA levels signiﬁcantly, by
75%, in the infected striatal region (Supplementary Fig. 2D).
We used lentiviruses expressing the N-terminal part of HTT
with a pathological expansion (Htt171-82Q) that we have
previously shown to model Huntington’s disease and to pro-
duce striatal lesions in a consistent manner (Galvan et al.,
2012; Ruiz and Deglon, 2012; Francelle et al., 2015b, d).
ShCTRL or shDCLK3 was co-expressed with Htt171-82Q
in the mouse striatum. We used GFP expression levels as
readout of neuronal integrity at 3 and 6 weeks post-infection.
For each mouse, 3D determination of striatal GFP levels was
performed by direct measurement of ﬂuorescence levels using
serially cut adjacent brain sections encompassing the entire
striatum. GFP levels in the striatum were low 3 and 6
weeks after infection with the LV-Htt171-82Q, while in the
shCTRL group (without mHtt) ﬂuorescence levels remained
high. The loss of GFP (30%) was only a trend at 3 weeks
post-infection in the mHtt/shCTRL group as compared to
shCTRL (Fig. 1A and B). In the group expressing mHtt
and shDCLK3, the loss at 3 weeks post-infection was more
profound and reached statistical signiﬁcance as compared to
control (shCTRL without mHtt). At 3 and 6 weeks post-in-
fection, the mHtt-induced loss of ﬂuorescence in the striata
expressing shDCLK3 was signiﬁcantly more pronounced than
that seen in striata expressing the shCTRL. These results
indicated that mHtt-induced loss of ﬂuorescence, an index
of neurodegeneration, was accelerated by the expression of
shDCLK3 in the mouse striatum (Fig. 1A and B). Tri-dimen-
sional measurement of the volume of the striatal lesions using
DARPP32 immunohistochemistry conﬁrmed that Htt171-
82Q-induced disease was more pronounced in striata express-
ing shDCLK3 than in striata expressing shCTRL (Fig. 1C).
We then investigated whether the expression of rDCLK3s
in striatal neurons modiﬁed the toxicity associated with
mHtt production in vivo. The role of each mouse DCLK3
form was investigated with lentivirus coding for mouse re-
combinant L-DCLK3 and S-DCLK3 with a HA-tag at the
C-terminus (LV-L-rDCLK3-HA and LV-S-rDCLK3-HA, re-
spectively, Supplementary Fig. 2A). We injected LV-LacZ
(control vector), LV-S-rDCLK3-HA or LV-L-rDCLK3-HA
with LV-Htt171-82Q into the mouse striatum. In infected
animals, the expression of the S- and L-rDCLK3 proteins in
the striatum at 4 weeks post-infection could be checked by
HA-tag immunohistochemistry (Fig. 2A) and western blot
analysis (Supplementary Fig. 2E). Six weeks after infection,
pathological features, characterized by the loss of the
medium-sized spiny neuron marker DARPP32, neuronal
marker (NeuN), and cytochrome c oxidase (COX), were
observed in the striatum, in the control group (Fig. 2B, D
and F). The area of lesions seen in the rostro-caudal exten-
sion of the striatum in serially cut coronal brain sections
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(ﬁve to eight sections depending on the animals) were
quantiﬁed and used to determine the volume of the lesions
with the Cavalieri method. The volume of the lesions mea-
sured using DARPP32 staining in mice co-expressing
Htt171-82Q with L- or S-rDCLK3-HA was similar to
that seen in mice co-expressing Htt171-82Q with the con-
trol protein (Fig. 2B and C). However, in mice co-express-
ing Htt171-82Q with either L- or S-rDCLK3-HA, the
lesions detected using NeuN and COX staining were
signiﬁcantly attenuated with respect to the control group
(Fig. 2D–G). The number of ubiquitin-positive aggregates
in the entire striatum was also quantiﬁed by image analysis
in ﬁve to eight serially-cut sections in all the mice infected
with LV-171-82Q (Fig. 2H and I). No signiﬁcant difference
was found between groups, suggesting no major impact of
rDCLK3 on mHtt accumulation.
Thus, DCLK3 knockdown exacerbates mHtt-induced de-
generation whereas DCLK3 overexpression is neuroprotec-
tive against mHtt toxicity in vivo.
DCLK3 improves motor signs in
knock-in 140CAG mice
As we observed that DCLK3 could produce neuroprotec-
tion (i.e. blockade of cell death) without total rescue of the
Figure 2 Effect of mouse recombinant DCLK3-HA overexpression on the toxicity of mHtt. Adult male mice received a bilateral
intrastriatal injection of a mixture of two lentiviral vectors (LV): LV-Htt171-82Q with LV-CTRL (LV-LacZ, control), LV-S-rDCLK3-HA or LV-L-
rDCLK3-HA. Six weeks after infection, brains were processed for histological evaluation by immunostaining for the HA-tag, DARPP32, NeuN,
and ubiquitin, and histochemistry for cytochrome c oxidase (COX) detection, to evaluate Htt171-82Q neurotoxicity. Coronal sections of mouse
brains displaying a representative area with rDCLK3-HA overexpression (A) or depletion of staining, for the different groups (B, D, F and H).
(C, E, G and I) Quantitative determination of the volume of the striatal lesions in the different groups using serial sections for each animal. Results
are expressed as means (n = 7–10/group)  the SEM. One-way ANOVA and Fisher’s post hoc PLSD test. Scale bars = AH (A), 0.2 mm; NeuN
(B), 0.1 mm; Cox (D), 0.5 mm; ubiquitin (F), 0.125 mm.
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molecular phenotype of medium-sized spiny neurons (loss
of DARPP32), we asked whether DCLK3 could produce
beneﬁcial effects on the function of striatal neurons in the
KI140CAG mouse model of Huntington’s disease
(Menalled et al., 2003). In heterozygous and homozygous
knock-in 140CAG Huntington’s disease mice at 12 months
of age, we found that striatal Dclk3 mRNA levels were
signiﬁcantly lower than in control littermates
(Supplementary Fig. 3) as found by others (Langfelder
et al., 2016). We therefore investigated whether the restor-
ation of DCLK3 expression in the striatum of these mice
could improve their well-characterized Huntington’s disease
behavioural phenotype (Menalled et al., 2003; Pepin et al.,
2016). We used the AAV2/rh10 vector (AAV-L-rDCLK3
and AAV-GFP as control) to produce L-rDCLK3-HA
throughout much of the striatum (Fig. 3A, B). This led to
markedly higher levels of mRNA production than for the
endogenous mouse Dclk3 (Fig. 3C). Homozygous
KI140CAG mice underwent bilateral injections before the
onset of symptoms, at the age of 6 months (Fig. 3D).
Mice were studied in the rotarod motor test. The time for
which the animals were able to remain on the rotarod was
signiﬁcantly shorter in uninjected Huntington’s disease mice
and GFP-expressing Huntington’s disease mice than in litter-
mate controls at the age of 12 months in accelerating speed
trials (Fig. 3E). Rotarod performance of L-DCLK3-expressing
Huntington’s disease mice was not signiﬁcantly different from
that of control littermates and signiﬁcantly better than the
performance of uninjected and GFP-expressing Huntington’s
disease mice.
Consistent with the ﬁndings of the rotarod test, GFP–ex-
pressing Huntington’s disease mice also performed signiﬁ-
cantly less well in forelimb grip strength tests than
GFP-expressing wild-type littermates. By contrast, the
long-term overexpression of L-rDCLK3 alleviated the grip
strength defects of Huntington’s disease mice at 12 months
of age. Indeed, there was a signiﬁcant difference between
KI140CAG Huntington’s disease mice receiving AAV-GFP
injections and wild-type mice, whereas Huntington’s disease
mice receiving injections of AAV-L-rDCLK3 did not differ
from wild-type mice in terms of grip strength (Fig. 3F).
We also used the CatWalk system to investigate gait
deﬁcits in the Huntington’s disease mice. Body speed was
signiﬁcantly increased in Huntington’s disease mice injec-
tion with AAV-GFP when compared to wild-type mice.
Body speed varied signiﬁcantly less in Huntington’s disease
mice overexpressing L-rDCLK3 than in Huntington’s dis-
ease mice expressing GFP (Fig. 3G), indicating a more
homogeneous displacement. Consistent with this ﬁnding,
we also observed fewer twitches in the gait of
Huntington’s disease mice overexpressing DCLK3 than in
that of those expressing GFP (Fig. 3H).
Moreover, the body weight of Huntington’s disease mice
overexpressing L-rDCLK3 increased over the 6 months of
the experiment, whereas that of Huntington’s disease mice
expressing GFP remained stable over time after infection
(Fig. 3I).
Thus, the restoration of DCLK3 expression improves
motor and health signs in KI140CAG mice.
Neuroprotection is mediated by the
kinase domain of DCLK3
The tandem DCX domains of DCLK1 and DCLK2 play a
major role in the known functions of these proteins in
neurodevelopment and neuroprotection, through inter-
action with cytoskeletal elements (Ohmae et al., 2006a;
Shin et al., 2013; Nawabi et al., 2015). The tandem
DCX domains are not conserved in human DCLK3 and
mouse S-DCLK3. Mouse L-DCLK3 has only one DCX
domain. We therefore hypothesized that the kinase
domain underlies key functions of DCLK3, including its
neuroprotective effect against mHtt. To address this ques-
tion, we generated different rDCLK3 mutants.
We ﬁrst generated a truncated mouse DCLK3 protein con-
taining only the kinase domain [aa 159–619], by deleting the
N-terminal DCX domain (Kin-rDCLK3-HA) (Fig. 4A).
Wild-type mice were co-infected with LV-Htt171-82Q
together with either LV-CTRL (coding LacZ) or LV-rKin-
DCLK3. Histological analyses of staining for NeuN and
COX showed that the volumes of striatal lesions were sig-
niﬁcantly decreased by the overexpression of Kin-rDCLK3
(Fig. 4B and C). Thus, overexpression of the rDCLK3 kinase
domain is sufﬁcient for neuroprotection against mHtt
toxicity.
We then investigated whether the disruption of kinase
activation abolished the neuroprotective efﬁcacy of the pro-
tein against mHtt. We generated a T2864A (T286A) sub-
stitution in S-rDCLK3 (similar to Th289 in human
DCLK3) within a conserved motif of charged amino acids
similar to that close to threonine 286 in CaMKII, which is
known to play a major role in activation. We investigated
the effect of this mutation on the toxicity of mHtt in cul-
tured striatal neurons. Cell death was evaluated by count-
ing transfected neurons with fragmented nuclei. The
overexpression of mHtt (Htt171-82Q) led to neuron degen-
eration in primary striatal cultures, with an increase in
the number of fragmented nuclei. Wild-type S-rDCLK3
was neuroprotective against mHtt toxicity, whereas the
S-rDCLK3T286A mutant was not (Supplementary Fig. 4).
We checked that kinase activation was a critical event for
the neuroprotective function of DCLK3 by generating ‘dead
kinase’ mutants of L-rDCLK3 and Kin-rDCLK3 (Fig. 4A).
We identiﬁed a highly conserved lysine residue (K543) in
the ATP-binding pocket as the target (Supplemental
Supplementary Fig. 5). Substitutions of this residue have
been shown to abolish kinase activity in other kinases
(e.g. AKT1, AMPK). We generated L-rDCLK3K543M and
Kin-rDCLK3K543M mutants (K4M). As expected, these
mutants displayed much lower levels of autophosphoryla-
tion than the wild-type forms in an assay with [-32P]-ATP
(Fig. 4D). Consistent with this ﬁnding, L-rDCLK3K543M
and Kin-rDCLK3K543M phosphorylated the pan-kinase
1444 | BRAIN 2018: 141; 1434–1454 L. Galvan et al.
substrate MBP only inefﬁciently when compared to the
wild-type form of Kin-rDCLK3 (Fig. 4E). These experi-
ments validate these mutants as ‘dead DCLK3 kinase’
proteins.
We then investigated the effects of the ‘efﬁcient kinase’
DCLK3 (Kin-rDCLK3) and the ‘dead kinase’ DCLK3
(Kin-rDCLK3K543M) on the toxicity of mHtt (Htt171-
82Q) in mouse striatum in vivo. The detection of the
HA-tag by immunohistochemistry in vivo 6 weeks after
lentiviral injection showed that expression levels were
similar for Kin-rDCLK3K543M and the wild-type form
(not shown). The volume of the mHtt-induced striatal
Figure 3 Functional effects of striatal overexpression of L-rDCLK3, using AAV2/rh10 in homozygous KI140 Huntington’s
disease mice. (A) Schematic representation of the adeno-associated-virus (AAV) constructs used to overexpress GFP (control) or L-rDCLK3 in
mice (with AAV2/rh10). (B) Typical image of AAV–mediated transduction of the mouse striatum with AAV-GFP. (C) DCLK3 levels in striatum
infected with AAV-L-rDCLK3-HA in KI140 mice, as assessed by RT-qPCR. (D) Time course and experimental design: mice received injections of
AAV-GFP or AAV-L-rDCLK3 (n = 7 for the GFP group and n = 8 for the L-DCLK3 group) at the age of 6 months. At 12 months of age, mice
performed rotarod, grip strength and CatWalk tests. (E) Accelerated rotarod test: the results of the three tests (t1, 2, 3) on the last training day
are shown. (F) Grip strength was measured in triplicate for all animals. (G) The CatWalk parameter ‘mean body speed variation’ was measured to
evaluate the smoothness of displacement. (H) Number of twitches captured in the acquisition window during the run (short and sudden jerking of
one of the paws). (I) Body weight of the KI140 mice after striatal infection. Results are expressed as means (n = 7/group)  SEM. P-values indicate
significance levels: ANOVA for repeated measures over the three tests in E; one-way ANOVA factorial analysis in F, G and H, followed by Fisher’s
post hoc PLSD test).
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Figure 4 The active kinase domain of rDCLK3 is sufficient to protect against mHtt in the striatum in vivo. (A) Schematic
illustration of DCLK3 and Kin-rDCLK3-HA constructs with and without the K543M mutation. (B) Mice received bilateral injection of LV-Htt171-
82Q mixed with either LV-LacZ (control) or a lentivirus encoding the kinase domain of DCLK3 (LV-Kin-rDCLK3). Six weeks after infection, brains
were processed for histological evaluation (B) of NeuN, HA and COX (not shown) levels. HA staining (B) shows expression of Kin-rDCLK3-HA
in the striatum. (C) Quantification of the volumes of the Htt171-82Q-induced striatal lesions by staining for NeuN, COX and ubiquitin.
(D) Autophosphorylation experiments with ATP [-32P] after the co-immunoprecipitation of wild type or mutant Kin-rDCLK3 with anti-HA
antibody followed by SDS-PAGE, showing the incorporation of radioactive 32P into the protein. Colours indicate the radioactivity levels from
white (no signal) to red (highest). (E) Assays of kinase activity, with MBP used as a kinase substrate after the of Kin-rDCLK3-HA, wild-type (WT)
and mutant K543M forms (K4M) and detection of phosphorylated MBP (p-MBP) by western blotting. T = input (total protein extract before
immunoprecipitation), S = sample test; n.t. = non-transfected cells (control). (F and H) Photomicrographs showing striatal lesions in mice injected
with LV-Htt171-82Q mixed with LV-LacZ (control, CTRL), LV-Kin-rDCLK3 (WT) or lentivirus encoding the mutant Kin-DCLK3 form with the
K543M (K4M) substitution. (G and I) Histograms representing the quantification of the volumes of Htt171-82Q-induced lesions using NeuN
(G) and COX (I) staining. Scale bars = 0.2 mm. Results are expressed as means (n = 7–11/group)  SEM. P-values indicate the level of significance
(unpaired Student’s t-test, control versus wild-type).
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lesions was measured using NeuN and COX staining. It
was signiﬁcantly reduced by the co-expression of Kin-
rDCLK3 in striatal neurons (Fig. 4F–I). By contrast, striatal
neurons were not rescued by Kin-rDCLK3K543M co-expres-
sion (Fig. 4F–I).
Thus, the kinase function of DCLK3 is critical for neu-
roprotection against mHtt.
DCLK3 behaves as a regulator of
chromatin biology and transcription
Following the demonstration that the DCLK3 kinase
domain was required for neuroprotection, we looked for
downstream effectors, by identifying potential interactors.
The human Kin-DCLK3 domain (aa 162–632) (Fig. 5A)
was used as a bait in a yeast two-hybrid screen to identify
potential partners from a human brain library. We identi-
ﬁed seven interactors: TADA3, BTBD9, TRIM39, SALL1,
ZNF12, ZNF292 and ZNF366 (Fig. 5B and Supplementary
Table 1). The protein interactions from this screen have
been submitted to the IMEx (http://www.imexconsortium.
org) consortium through IntAct (Orchard et al., 2014) and
assigned the identiﬁer IM-26152. All the interactors
identiﬁed have zinc ﬁnger domains. Bioinformatics-based
searches for potential functions (based on similarity)
suggested that these DCLK3 interactors were involved
in transcription. TADA3 appeared to be the most relevant
of the interactors identiﬁed, as the level of conﬁdence
for interaction with DCLK3 was highest for this molecule.
Furthermore, an analysis of the expression of the genes
encoding these seven interactors in the brain based
on previously reported mouse SAGE data (Brochier et al.,
2008), or more recent region- and cell type-speciﬁc
transcriptomic databases (http://mouse.brain-map.org/;
http://web.stanford.edu/group/barres_lab/brain_rnaseq.html)
(Supplementary Table 1) revealed that TADA3 was more
strongly expressed in the striatum than the other DCLK3
interactors. It was strongly expressed in neurons and other
brain cell types. We obtained evidence supporting DCLK3–
TADA3 interaction, by performing co-transfection followed
by co-immunoprecipitation. HA-tagged rDCLK3 and a
V5-tagged form of one of its potential partners, TADA3,
were expressed in HEK293T cells. Co-immunoprecipitation
experiments were conducted with whole-cell lysates pre-
pared from the co-transfected cells. TADA3-V5 co-immu-
noprecipitated with Kin-rDCLK3-HA. Kin-rDCLK3-HA
was also co-immunoprecipitated with TADA3-V5
(Fig. 5C).
The TADA3 protein (transcriptional adapter 3, also
called ADA3) is a component of the Spt-ada-Gcn5 acetyl-
transferase (SAGA) complex. This complex regulates tran-
scription by modulating histone post-translational
modiﬁcations, including histone acetylation (Wang et al.,
2008). TADA3 has a large number of known partners,
including TADA2, several TATA box-binding protein-asso-
ciated factors (TAFs), the histone acetyltransferases KAT2B
and KAT2A, and the transcription initiation protein SPT3
homolog SUPT3H (Fig. 5B), providing strong support for
the hypothesis that DCLK3 could regulate transcription
through SAGA-induced histone modiﬁcations.
We asked whether the DCLK3 kinase domain could
modulate transcriptomic proﬁle in neurons. We overex-
pressed human Kin-rDCLK3WT, Kin-rDCLK3K543M or
GFP (as a control) in striatal neurons derived from wild-
type human embryonic stem cells (Fig. 6A) using lentiviral
vectors. After 10 days, we performed transcriptome
analyses by ultrahigh-multiplex PCR (Ion AmpliSeq tech-
nology). A relatively stringent analysis of differential gene
expression (fold-change 1.2; P5 0.0005, FDR, 0.05) be-
tween cells expressing Kin-rDCLK3WT and cells expressing
GFP showed that 88 genes were upregulated and 73 down-
regulated in the presence of Kin-rDCLK3WT (Fig. 6B
and Supplementary Table 2; GEO dataset GSE104091).
Kin-rDCLK3 modiﬁed the expression levels of many
genes encoding histones and transcription-related proteins.
Gene ontology analyses with DAVID (Huang da et al.,
2009) and GREAT (McLean et al., 2010) indicated that
the upregulated genes were signiﬁcantly enriched in func-
tions and pathways linked to chromatin biology and
nucleosomes, whereas the downregulated genes showed
no signiﬁcant enrichment in any speciﬁc function or
pathway (Fig. 6 and Supplementary Fig. 6). Speciﬁcally,
we observed an upregulation of genes encoding histones
(HIST) and proteins modulating chromatin state and
transcription dynamics, including MLL5 [KMT2E lysine
(K)-speciﬁc methyltransferase 2E], TAF7 (transcription
initiation factor TFIID 55kDa subunit) and SUPT3H
(SPT3 homologue). Like TADA3, SUPT3H is a core com-
ponent of the SAGA complex (Wang et al., 2008).
We then identiﬁed genes for which expression levels were
selectively modiﬁed by the catalytic activity of the kinase
domain. We took the set of genes for which expression was
signiﬁcantly modiﬁed by Kin-rDCLK3WT (Supplementary
Table 3), and identiﬁed those that also displayed signiﬁcant
differences in expression between Kin-rDCLK3WT and Kin-
rDCLK3K543M conditions (Supplementary Table 4). There
were 53 genes present on both lists (i.e. 9-fold enrichment)
(Fig. 6C, Supplementary Tables 4 and 5). Many of these
genes whose expression was regulated by DCLK3 in a
kinase-dependent manner are involved in transcription
regulation. They included the genes encoding the demethy-
lase ZIC3 and the zinc ﬁnger domain-containing BTBD9
protein identiﬁed as a potential partner of human
Kin-DCLK3 in the yeast two-hybrid screen described
above. Eight of these genes encoded histones (HIST).
Most of these genes (64%) were upregulated.
Approximately 40% of these genes were found also to be
signiﬁcantly deregulated in knock-in mouse models of
Huntington’s disease (Langfelder et al., 2016), suggesting
a link between decreased DCLK3 and altered regulation of
genes implicated in chromatin biology and transcription.
To further investigate this relationship, using lentiviral
vectors, we overexpressed a truncated version of mHtt,
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together with Kin-rDCLK3WT or Kin-rDCLK3K543M or
GFP (as a control), in striatal neurons derived from wild-
type human embryonic stem cells (Fig. 6D). After 10 days,
we performed expression analyses, using qRT-PCR. More
speciﬁcally, we analysed 24 genes of the above list of 53
genes (whose expression, in the absence of mHtt was chan-
ged both in cells expressing Kin-rDCLK3WT versus cells
expressing GFP and in cells expressing Kin-rDCLK3K543M
versus cells expressing Kin-rDCLK3WT cells). Subsets of
these genes, including BTBD9 and histones, were also
modulated by Kin-rDCLK3 in the context of the
Huntington’s disease mutation (Fig. 6D), through a
kinase-dependent manner, suggesting that the protective
effect of DCLK3 in neurons expressing mHtt involves epi-
genetic and/or transcriptional mechanisms. Additionally,
we examined the effect of rDCLK3 overexpression on the
striatal marker genes, PPP1R1B (DARPP32), TAC1 and
PDE10A, which are decreased in the Huntington’s disease
pathology. Expression of PPP1R1B/DARPP32 and TAC1
was not markedly changed by Kin-rDCLK3WT or by
Kin-rDCLK3K543M in Huntington’s disease-like human
cells, a result that is consistent with results found in
our lentiviral mouse models. In contrast, Kin-rDCLK3WT,
and not Kin-rDCLK3K543M increased the expression of
PDE10A, an important regulator of striatal physiology,
further suggesting that restoring DCLK3 signalling is
beneﬁcial in Huntington’s disease-like striatal neurons.
Since these data suggested that DCLK3 may act in the
nucleus, we studied the subcellular localization of endogen-
ous DCLK3 and rDCLK3. The endogenous levels of mouse
DCLK3 is low and could not be easily detected with the
commercially available human anti-DCLK3 antibodies. For
this reason, we ﬁrst investigated whether DCLK3 could be
detected by immunoﬂuorescence in primary culture of rat
neurons. We used an antibody directed against the internal
N-terminal part of human DCLK3 (Ab2189, Novus)
(Fig. 7A). Confocal imaging showed a relatively weak
immunoﬂuorescent signal in the cytoplasm and nucleus of
neurons (Fig. 7B). When the primary Ab2189 antibody was
omitted and when the antibody was pre-blocked with the
recombinant human DCLK3 protein this signal markedly
decreased (Supplementary Fig. 7A). When neurons were in-
fected with LV-S-rDCLK3-HA, immunoﬂuorescence signal
related to the antibody Ab2189 increased in the cytoplasm
and the nucleus as compared to not-infected cells (Fig. 7B).
We could also detect Kin-rDCLK3 protein by immunoﬂuor-
escence in the cytoplasm and in the nucleus of human
striatal neurons expressing mHtt (Supplementary Fig. 8).
L-rDCLK3-HA could be detected by the anti-HA antibody
in LV-infected mice in vivo. The HA-tag was mainly found
in the cytoplasm of striatal neurons. Cytoplasmic rDCLK3
related ﬂuorescence was also detected with Ab 2189, which
cross reacts with the mouse protein when overexpressed (not
shown). Interestingly, signal was also found in the nucleus of
transduced striatal neurons (Fig. 7C). This suggested that a
cleaved product of DCLK3 lacking its C-terminal part
(therefore lacking the HA-tag) accumulated in the nucleus
in vivo. This ﬁnding is reminiscent of the reported migration
of DCLK2 to the nucleus after the cleavage of a short
C-terminal domain (Nagamine et al., 2014).
To check that the nuclear localization of DCLK3 in
rat and mouse neurons was not an artefact related to its
overexpression after lentiviral-mediated transduction, we
analysed the distribution of endogenous DCLK3 in non-
human primate brains with the anti-DCLK3 antibody (Ab
2189). In the caudate-putamen prepared from parafﬁn-
embedded section, immunohistochemical analysis of the
striatum showed DCLK3 to be present in the nucleus of
neurons (Fig. 7D). Subcellular fractionation of homogen-
ates prepared from non-human primate striatum showed
the non-human primate DCLK3 protein (74 kDa) to be
present in both the cytoplasm and the nucleus (Fig. 7E). We
performed immunoﬂuorescence detection of DCLK3 on
ﬂoating sections. Confocal microscopy showed DCLK3 to
be present in the nucleus of many cells that were positive
for the neuronal marker NeuN, consistent with the expres-
sion of the protein in medium-sized spiny neurons in this
brain region (Fig. 7F and G). DCLK3 immunoﬂuorescence
decorates the chromatin in the vicinity of the nuclear
Figure 5 Yeast two-hybrid screen of interactors of the
DCLK3 kinase domain. (A) The C-terminal domain of human
DCLK3 (Kin-DCLK3) was used as bait to screen a human brain
mRNA library. (B) The seven proteins (in bold) were found to interact
with DCLK3. String 10.0 bioinformatics software (http://string-db.org)
was used to search for TADA3 (Transcriptional adapter 3) interactors
(human only) in public databases and for the schematic representation
of the network of functional interactions for TADA3. (C) Interaction
between Kin-DCLK3 and TADA3 was checked in double pull-down
experiments after the transfection of HEK cells.
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membrane, consistent with nucleosomal localization, as
suggested from a bioinformatics search (e.g. http://www.
genecards.org/cgi-bin/carddisp.pl?gene=DCLK3). DCLK3
was detected both in the cytoplasm and the nucleus of stri-
atal neurons and in large neurons (layers V) of the cerebral
cortex (Supplementary Fig. 7B and C).
Together with the yeast two-hybrid screen and cellular
localization data, transcriptomic results support the view
that the DCLK3 in striatal neurons has a nuclear function
linked to chromatin biology and transcription regulation.
Discussion
This study identiﬁes for the ﬁrst time DCLK3 as a key
signalling kinase in the neurons likely to play a role in
Figure 6 Effect of rDCLK3 kinase domain in human striatal neurons. (A) Schematic representation of the lentiviral (LV) constructs
used to transduce human striatal neurons derived from neuronal stem cells for transcriptomic analysis of the effects of the rDCLK3 kinase domain
by AmpliSeq at 12 days post-infection. (B) Gene ontology analysis of genes (n = 88) significantly upregulated by Kin-rDCLK3WT using DAVID and
GREAT identified functions related to nucleosome and chromatin/DNA remodelling. (C) Genes with significant changes in expression dependent
on the catalytic activity of Kin-rDCLK3 (i.e. genes displaying significant differences in expression (FDR5 0.05) between Kin-rDCLK3WT and GFP
and between Kin-rDCLK3K543M and Kin-rDCLK3WT). (D) Expression levels of a subset of genes identified in C in human neurons expressing
Htt171-82Q and either GFP, Kin-rDCLK3WT or Kin-rDCLK3K543M. Expression levels where determined by RT-qPCR. Results are expressed as
means (C, n = 4 wells per group; D, n = 5–6 wells per group)  SEM. One-way ANOVA factorial analysis in D followed by Fisher’s post hoc PLSD
test. *P5 0.05.
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Figure 7 Nuclear localization of DCLK3 in striatal neurons. DCLK3/rDCLK3 proteins were detected with an anti-HA antibody (green)
and an anti-DCLK3 antibody (Ab2189; red) recognizing the internal domain of the protein. (A) Schematic representation of the immunodetection
of endogenous and recombinant DCLK3. (B) Endogenous rat DCLK3 (top) and mouse rDCLK3 expressed with a lentiviral vector (bottom) in
primary culture of rat cortical neurons. Note DCLK3 is present in both the cytoplasm and nucleus. (C) Cellular distribution of DCLK3 after the
injection of LV-L-rDCLK3-HA into the mouse striatum, as determined with confocal images indicate the presence of DCLK3-HA in the cytoplasm
(green) and of a form of DCLK3 lacking the C-terminal HA tag in the nucleus of the neurons (red). (D) Immunohistochemical detection of
endogenous DCLK3 in the non-human primate caudate nucleus with an antibody recognizing the internal domain of the protein (Ab2189).
Arrowheads indicate cells with essentially nuclear distribution (dark staining) of DCLK3. (E) Western blot analysis of DCLK3 levels in fractions
(total homogenates = T; cytosol = Cyt; Nuclear = Nu) prepared from non-human primate caudate/putamen, showing the full-length (f.l.) protein
and the putative cleaved product of the protein (cleaved). DCLK3 is both in the cytoplasm and nucleus. (F) Confocal images of endogenous
DCLK3 (red), obtained with the Ab2189 antibody along with NeuN (green) and nuclear DNA (blue) in the non-human primate caudate nucleus.
(G) Enlarged view of the two fields of view (1 and 2) in the image in B in the three fluorescence channels. The perimeter of the nucleus is
delineated (white dotted lines). Scale bars in B and D = 10mm, C and G = 5mm.
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the susceptibility of striatal neurons to mHtt. Our results
also provide evidence for a role of DCLK3 in a nuclear
function linked to chromatin and transcription regulation,
a function that is altered early in Huntington’s disease.
DCLK3 levels are low in Huntington’s disease patients
and animal models (Kuhn et al., 2007; Langfelder et al.,
2016). We conﬁrmed this observation using qRT-PCR in
our KI140CAG Huntington’s disease mice. Our results in-
dicate that DCLK3 is neuroprotective against mHtt in
murine medium-sized spiny neurons in vivo and that
DCLK3 downregulation exacerbates mHtt toxicity.
Intriguingly, expression of rDCLK3 did not restore
DARPP32 levels while it rescued NeuN and COX levels
in our in vivo models. Consistent with this, in human stri-
atal neurons expressing mHtt, rDCLK3 did not change
DARPP32 levels while levels of PDE10A, another well es-
tablished marker of striatal neurons were increased in a
kinase-dependent manner. The total number of ubiquitin-
positive inclusions was not changed by rDCLK3 while in
the striatal volume infected expressing mHtt the number of
surviving neurons was likely increased by the kinase. Thus
it is possible that the net number of inclusions per neurons
was reduced, suggesting rDCLK3 may slightly diminish
mHtt aggregation. Whether this could contribute to the
neuroprotective effects of rDCLK3 awaits further studies.
Thus, early decreases in DCLK3 levels in the striatum in
Huntington’s disease may render medium-sized spiny neu-
rons more susceptible to complex disease processes leading
eventually to neuronal cell death. The neuroprotection con-
ferred by rDCLK3 was observed in an acute in vitro model
of Huntington’s disease, and in a relatively ‘aggressive’
mouse model of Huntington’s disease based on the over-
expression of a short N-terminal fragment of mHtt, leading
to severe neuronal marker loss and cell death within a few
weeks. We also investigated the neuroprotective potential
of rDCLK3 in a highly progressive ‘mild’ mouse model of
Huntington’s disease, KI140CAG mice. We found that
rDCLK3 overexpression improved mouse motor perform-
ance. Thus our results suggest that increased DCLK3 sig-
nalling in the striatum can improve neuronal dysfunction,
supporting the hypothesis that the loss of DCLK3 function
in KI140 Huntington’s disease mice could play a role in the
motor signs in these animals. These observations highlight
the probable role of early DCLK3 loss in precipitating both
striatal dysfunction and associated motor symptoms in
Huntington’s disease.
‘Striatal enriched’ gene products other than DCLK3 have
been identiﬁed as potentially involved in the selective degen-
eration of the striatum in Huntington’s disease (for a review
see Francelle et al., 2014). These gene products include for
example the Ras-related protein Rhes (Subramaniam et al.,
2009), the thyroid hormone binding protein CRYM
(Francelle et al., 2015b), and the non-coding RNA
Abhd11os (Francelle et al., 2015d). Thus, the additive
and/or synergistic loss of several striatal markers, including
DCLK3, may render the striatum particularly sensitive to
mHtt toxicity in Huntington’s disease.
The mechanisms underlying the neuroprotection pro-
duced by rDCLK3 are unknown. High expression levels
of DCLK3 have been recently shown to be a key risk
factor in colorectal cancer through the modiﬁcation of the
expression of genes (associated to epithelial-to-mesenchy-
mal transition) that drive tumour cells into a more aggres-
sive behaviour (Liu et al., 2017). Thus high DCLK3 levels
might be associated with anti-apoptotic pathways, which is
consistent with its neuroprotective effects we found in the
present study. However, nothing is known of the roles of
DCLK3 in adult neurons. The present study provides novel
results that may help understanding these probably com-
plex mechanisms. We showed that the expression of a
mouse truncated protein containing only the kinase
domain of DCLK3 conferred neuroprotection against
mHtt. We also showed that a ‘dead’ kinase form of
DCLK3 was unable to mediate such neuroprotection,
thereby demonstrating that the neuroprotective effect of
DCLK3 against mHtt requires the catalytic kinase activity
of the protein. These ﬁndings suggest that the function of
the kinase domain of DCLK3 may be speciﬁc. DCLK1 and
DCLK2 are also neuroprotective and their overexpression
can improve neuroregeneration after axonal injury
(Nawabi et al., 2015). The role of the kinase domain of
DCLK1/2 in these effects is unlikely, because the overex-
pression of the DCX domains and of the adjacent S/P-rich
domain in the absence of the kinase domain seems to be
sufﬁcient to improve regeneration. Similarly, DCLK1/2 can
regulate the spindle orientation of neuronal precursors
during mitosis and cortical development independently of
kinase activity (Shu et al., 2006). In addition, DCLK3 dis-
plays a more neuron-speciﬁc pattern of expression
than DCLK1/2, which are also expressed in astrocytes
(http://web.stanford.edu/group/barres_lab/brain_rnaseq.html)
(Zhang et al., 2014). Bioinformatics tools to compare
DCLK3 and the other two members of the DCLKs family
indicate that while the structure/organization of the kinase
domain is conserved, many amino acids are different in the
kinase domain and in regions surrounding the kinase
domain (Supplementary Fig. 9). Thus it is tempting to specu-
late that interactors of Kin-rDCLK3 are different from those
of the kinase domain of DCLK1/2, leading to a speciﬁc
signalling in neurons. However, it cannot be totally ruled
out that the three members of the family have interactors in
common. The cell- and region-speciﬁc expression of DCLK3
and the key role of its kinase domain in neuroprotection
highlight differences in neurological functions of this
kinase and of DCLK1/2.
The present ﬁndings also suggest that DCLK3 has nu-
clear functions. Following its overexpression in mouse stri-
atum, DCLK3 was detected in both the cytoplasm and the
nucleus. Fractionation experiments and confocal imaging
on non-human primate striatum indicated that DCLK3
was preferentially localized in the nucleus, despite the de-
tection of some DCLK3 in the cytoplasm. This ﬁnding is
consistent with the observation that DCLK2 enters the nu-
cleus after the cleavage of its C-terminus (a probable
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‘regulatory domain’) (Nagamine et al., 2014).
Translocation from the cytoplasm to the nucleus has also
been suggested for DCLK1 (Burgess and Reiner, 2001;
Kuribara et al., 2011). Autophosphorylation assays sug-
gested that a DCLK3 protein with an apparent molecular
weight close to that of the full-length form had the highest
level of catalytic activity. The nuclear location of DCLK3
may, therefore, be an important aspect of its neuronal
function.
The yeast two-hybrid screen revealed that the proteins
interacting with the DCLK3 kinase domain were related
to transcriptional regulation and/or chromatin remodelling.
One of these interactors, the transcriptional activator adap-
tor TADA3, is a component of the SAGA complex linking
histone acetylation to the transcription machinery and is of
particular interest in this context. SAGA plays a key role in
transcription, regulating the transcription of almost all
genes in yeast and human cells (Bonnet et al., 2014). Its
importance in neurodevelopment and possibly neurodegen-
erative diseases has been recently underscored (Wang and
Dent, 2014). Expression of the DCLK3 kinase domain in
human striatal-differentiated embryonic stem cells leads to
the upregulation of genes encoding histones and proteins
modulating chromatin state and transcription dynamics,
suggesting that DCLK3 may play a direct role in chromatin
remodelling and transcription regulation. Our results in
human neurons expressing mHtt fragment suggest that
this function of DCLK3 is partially restored upon re-ex-
pression of rDCLK3, at least in part through a kinase-de-
pendent manner. Whether this contributes to increased
expression of subsets of striatal markers (e.g. PDE10A)
will need to be further investigated. The precise mechan-
isms of SAGA regulation to generate cell-speciﬁc transcrip-
tional signatures are unknown. The interaction of DCLK3
with TADA3 may provide us with a novel means of im-
printing a SAGA-dependent transcriptional signature in
medium-sized spiny neurons. Given the neuron-speciﬁc ex-
pression of DCLK3, this might constitute a novel pathway
for regulating transcription in response to synaptic stimuli,
for example. Further studies are needed to validate this
hypothesis.
The deregulation of transcription in Huntington’s disease
has been studied in detail over the past 15 years
(Seredenina and Luthi-Carter, 2012). Transcriptomic
studies of the striatum in mouse models of Huntington’s
disease and Huntington’s disease patients have identiﬁed a
functional signature associated with downregulated genes
(Francelle et al., 2017). This signature is characterized by
enrichment in genes associated with biological functions
linked to neuronal activity (Kuhn et al., 2007; Seredenina
and Luthi-Carter, 2012; Achour et al., 2015). The genes
downregulated in Huntington’s disease striatum have
been shown to be regulated by super-enhancers (Achour
et al., 2015), a category of enhancers controlling cell-type
speciﬁc identity through epigenetic mechanisms (Whyte
et al., 2013). Super-enhancers were also shown to be se-
lectively impaired in the striatum of mice with Huntington’s
disease, due to low levels of histone acetylation (Achour
et al., 2015). DCLK3 is one of the genes downregulated
by the loss-of-function of ‘super-enhancers’ (Achour et al.,
2015). Thus, DCLK3 loss of function may be part of a
vicious cycle leading to major transcription defects and det-
rimental epigenetic changes underlying early neuronal dys-
function and eventually cell death. The validation of this
hypothesis awaits further studies.
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